Antimicrobial and Biocompatible Endotracheal Tubes

呼吸机相关性肺炎(VAP)发生在以下48-72小时(或更长时间) 气管插管占所有医院获得性肺炎病例的一半 肺炎。疾控中心的报告和许多临床研究表明，迫切需要 预防呼吸机相关感染，而不是打一场经常失败的战斗 预防获得性感染。为了回应这一未得到满足的需求，WynnVision LLC，WV将 利用抗菌但细胞相容(ABC)纳米技术的强大初步结果 在已生产的插管产品上涂上大衣，以开发一项新技术 消除或大大降低VAP/VAE。WV方法，受最近的 专利申请，将涉及多学科活动和第三方测试，以 协助向FDA申请批准。

Ventilator-associated pneumonia (VAP) occurs 48–72 hours (or more) following endotracheal intubation and accounts for half of all cases of hospital-acquired pneumonia. CDC reports and many clinical studies point to a critical need for preventing ventilator associated infections rather than fighting an often losing battle against acquired infection. Responding to this unmet need, WynnVision LLC, “WV” will leverage strong preliminary results for antimicrobial-but-cytocompatible (ABC) nano- overcoats on as-manufactured intubation products to develop a new technology for eliminating or greatly reducing VAP/VAE. The WV approach, protected by a recent patent application, will involve multidisciplinary activities and third party testing to facilitate approaching FDA for approval.